Sotagliflozin for Cardiotoxicity

(SPARTACUS Trial)

This trial tests sotagliflozin to determine if it can prevent heart damage caused by certain cancer treatments, specifically anthracyclines, in people with newly diagnosed lymphoma. Sotagliflozin targets specific proteins to help protect the heart. Participants will receive either the drug or a placebo (a pill with no active medication) to compare results. Those who might be a good fit for this trial include individuals with newly diagnosed lymphoma who are about to start high-dose anthracycline treatment. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to important medical advancements.

The trial information does not specify if you need to stop taking your current medications. However, if you are already on SGLT2 inhibitors, you cannot participate in the trial.

Previous studies have generally found sotagliflozin to be well-tolerated, though some side effects require attention. Commonly reported issues include urinary tract infections, diarrhea, and a serious diabetes-related condition called diabetic ketoacidosis. These side effects are similar to those of other drugs in the same category. Large studies involving over 30,000 patients have shown that sotagliflozin can effectively lower the risk of heart problems, such as strokes and heart attacks, particularly in individuals with diabetes and kidney issues. While some risks exist, the benefits may outweigh them for certain patients. Always consult a healthcare provider to determine how this treatment might fit into a health plan.¹²³⁴⁵

Sotagliflozin is unique because it offers a different approach to managing cardiotoxicity by targeting the sodium-glucose co-transporter (SGLT) pathways, specifically SGLT1 and SGLT2. Unlike traditional treatments for cardiotoxicity, which often focus on managing symptoms or preventing further damage, sotagliflozin works to protect heart function through its dual action on glucose and sodium reabsorption. Researchers are excited about this treatment because it could provide a more comprehensive protective effect on the heart, potentially reducing the risk of heart failure and improving outcomes for patients experiencing cardiotoxic effects.

Research has shown that sotagliflozin can significantly lower the risk of heart problems. For example, one study found it reduced heart attacks from 2.7 to 1.8 events per 100 people each year. It also helps reduce hospital visits and improves heart function in people with heart failure. Additionally, sotagliflozin has decreased deaths from heart issues and hospital stays due to heart failure. In this trial, participants will receive either sotagliflozin or a placebo to evaluate its potential in protecting the heart from damage caused by some cancer treatments.³⁶⁷⁸⁹